SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (33)9/19/2000 11:52:42 AM
From: scaram(o)uche  Read Replies (1) of 508
 
IJ:

There's tons of evidence that a change in the lymphokine profile in CF patients might benefit them. Thus, I did not say that you are "wrong in drawing the connection between CF and gamma interferon".

You asked if ITMN were headed in that direction, and if the MAb were pointing there.

The answer to that question is "no".

That's all I said. Thanks.

A change in lymphokine profiles will be beneficial for a variety of patients with fibrotic *and* inflammatory diseases.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News